Analysts Offer Insights on Healthcare Companies: Pieris Pharmaceuticals (NASDAQ: PIRS) and FibroGen (NASDAQ: FGEN)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pieris Pharmaceuticals (PIRSResearch Report) and FibroGen (FGENResearch Report).

Pieris Pharmaceuticals (PIRS)

William Blair analyst Matt Phipps maintained a Buy rating on Pieris Pharmaceuticals on May 25. The company’s shares closed last Friday at $3.66.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 4.7% and a 47.5% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Chinook Therapeutics, and Autolus Therapeutics.

Pieris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $7.50, a 94.8% upside from current levels. In a report issued on May 18, Jefferies also initiated coverage with a Buy rating on the stock with a $6.00 price target.

See today’s analyst top recommended stocks >>

FibroGen (FGEN)

William Blair analyst Andy Hsieh reiterated a Hold rating on FibroGen on June 25. The company’s shares closed last Friday at $26.64.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 10.4% and a 49.5% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Nektar Therapeutics, and Viking Therapeutics.

Currently, the analyst consensus on FibroGen is a Hold with an average price target of $42.80, which is a 61.0% upside from current levels. In a report issued on June 18, Mizuho Securities also maintained a Hold rating on the stock with a $29.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.